Biohaven (NYSE:BHVN) has outlined plans for new late stage clinical trials in immunology, neurology, and obesity, with pivotal studies scheduled to begin in 2026. The company has completed a major ...
Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need to be even stricter with its expenditures. | Biohaven is powering ahead ...
After an FDA rejection of its spinocerebellar ataxia (SCA) therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it ...
Biohaven Ltd BHVN shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The ...
Stocktwits on MSN
XENE stock rallies 50% on epilepsy trial data, but one analyst thinks rival Biohaven still has 'room to differentiate'
Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026. ・CEO Ian Mortimer said ...
An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...
InvestorsHub on MSN
uniQure shares jump 36% after news of FDA gene therapy chief’s departure
Shares of uniQure BV (NASDAQ:QURE) surged 36% on Monday after reports emerged that the head of the U.S. Food and Drug Administration’s vaccines and gene therapies division will step down, triggering ...
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Biohaven Ltd. today and set a price target of $30.00. Bratzel covers the Healthcare sector, focusing on stocks such as Cogent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results